Pyxis Oncology (PYXS) Total Non-Current Liabilities (2020 - 2024)

Pyxis Oncology (PYXS) has 5 years of Total Non-Current Liabilities data on file, last reported at $41.6 million in Q3 2024.

• Total Non-Current Liabilities for Q3 2024 came in at $41.6 million, down 14.6% year-over-year; the trailing twelve-month figure through Sep 2024 was $41.6 million (down 14.6% YoY), and the FY2023 annual result was $48.0 million, down 5.01% from the prior year.
• Total Non-Current Liabilities climbed to $41.6 million in Q3 2024 per PYXS's latest filing, from $38.6 million in the prior quarter.
• Over five years, Total Non-Current Liabilities peaked at $50.6 million in Q4 2022 and troughed at $3.9 million in Q4 2020.
• A 5-year average of $33.2 million and a median of $35.6 million in 2022 frame the typical range for Total Non-Current Liabilities.
• The sharpest annual moves came in 2021 and 2022: Total Non-Current Liabilities soared 385.42% in 2021, then sank 58.84% in 2022.
• A 5-year view of Total Non-Current Liabilities shows it stood at $3.9 million in 2020, then surged by 385.42% to $18.7 million in 2021, then surged by 170.23% to $50.6 million in 2022, then decreased by 5.01% to $48.0 million in 2023, then dropped by 13.31% to $41.6 million in 2024.
• Business Quant data shows PYXS's Total Non-Current Liabilities at $41.6 million in Q3 2024, $38.6 million in Q2 2024, and $36.1 million in Q1 2024.